Iteos Therapeutics Price Prediction
| ITOSDelisted Stock | USD 10.15 0.00 0.00% |
Momentum 46
Impartial
Oversold | Overbought |
Using Iteos Therapeutics hype-based prediction, you can estimate the value of Iteos Therapeutics from the perspective of Iteos Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Iteos Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Iteos because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Iteos Therapeutics after-hype prediction price | USD 10.15 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as delisted stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Iteos |
Iteos Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Iteos Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Iteos Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Iteos Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Iteos Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Iteos Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Iteos Therapeutics' historical news coverage. Iteos Therapeutics' after-hype downside and upside margins for the prediction period are 10.15 and 10.15, respectively. We have considered Iteos Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Iteos Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of Iteos Therapeutics is based on 3 months time horizon.
Iteos Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Iteos Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Iteos Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Delisted Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Iteos Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 0.00 | 0.00 | 0.00 | 7 Events / Month | 5 Events / Month | In about 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
10.15 | 10.15 | 0.00 |
|
Iteos Therapeutics Hype Timeline
Iteos Therapeutics is currently traded for 10.15. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Iteos is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is estimated to be very small, whereas the daily expected return is currently at 0.0%. %. The volatility of related hype on Iteos Therapeutics is about 0.0%, with the expected price after the next announcement by competition of 10.15. About 90.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.91. Some equities with similar Price to Book (P/B) outperform the market in the long run. Iteos Therapeutics recorded a loss per share of 4.73. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next estimated press release will be in about 7 days. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.Iteos Therapeutics Related Hype Analysis
Having access to credible news sources related to Iteos Therapeutics' direct competition is more important than ever and may enhance your ability to predict Iteos Therapeutics' future price movements. Getting to know how Iteos Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Iteos Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| IVVD | Invivyd | 0.03 | 8 per month | 5.48 | 0.17 | 20.85 | (10.92) | 46.37 | |
| SVA | Sinovac Biotech | 0.00 | 3 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| RVNC | Revance Therapeutics | 0.01 | 6 per month | 0.00 | (0.08) | 6.38 | (5.97) | 40.39 | |
| CKPT | Checkpoint Therapeutics | 0.05 | 7 per month | 1.42 | 0.10 | 2.33 | (2.52) | 62.14 | |
| SAGE | Sage Therapeutics | 0.06 | 8 per month | 1.70 | 0.04 | 3.61 | (3.48) | 37.83 | |
| CLYM | Climb Bio | 0.18 | 7 per month | 4.79 | 0.16 | 20.21 | (8.84) | 40.37 | |
| VIGL | Vigil Neuroscience | 0.01 | 8 per month | 1.63 | 0.12 | 5.09 | (2.49) | 241.38 | |
| ORTX | Orchard Therapeutics PLC | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| BCYP | Big Cypress Acquisition | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| GTHX | G1 Therapeutics | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Iteos Therapeutics Additional Predictive Modules
Most predictive techniques to examine Iteos price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Iteos using various technical indicators. When you analyze Iteos charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Iteos Therapeutics Predictive Indicators
The successful prediction of Iteos Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Iteos Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Iteos Therapeutics based on analysis of Iteos Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Iteos Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Iteos Therapeutics's related companies.
Story Coverage note for Iteos Therapeutics
The number of cover stories for Iteos Therapeutics depends on current market conditions and Iteos Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Iteos Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Iteos Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Iteos Therapeutics Short Properties
Iteos Therapeutics' future price predictability will typically decrease when Iteos Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Iteos Therapeutics often depends not only on the future outlook of the potential Iteos Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Iteos Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 40.5 M | |
| Cash And Short Term Investments | 494.6 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Iteos Stock
If you are still planning to invest in Iteos Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Iteos Therapeutics' history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| CEOs Directory Screen CEOs from public companies around the world |